Abbott Launches Digene Insta on the Go – Instant Relief from Acidity, Anytime, Anywhere
Abbott is redefining on-the-go wellness with the launch of Digene Insta On The Go—a ready-to-use antacid solution that delivers relief in just 2 seconds.
Business Wire India
Abbott is redefining on-the-go wellness with the launch of Digene Insta On The Go—a ready-to-use antacid solution that delivers relief in just 2 seconds. With Digene Insta On The Go, Abbott has introduced a ready-to-use, water-free solution that fits seamlessly into the fast-paced lives of today's consumers. It provides fast and effective relief from acidity, heartburn, and indigestion. 1 Developed for people with busy lifestyles, this fast-acting formula acts in just 2 seconds 2 —delivering convenience. Each 10 ml sachet is ready to use and effectively targets acidity and gas-related discomfort. It is designed for instant use, without the need for water, mixing, or measuring. Simply tear open the sachet and sip for direct relief. Digene Insta On The Go is now available in refreshing mint flavor at Rs.50 for a pack of five single-use sachets. Dr. Jejoe Karankumar, Director of Medical Affairs at Abbott, said, 'Acidity can strike without warning – during a hectic workday, while traveling, or even on your daily commutes 3,4 . This ready-to-use, handy solution delivers rapid relief within seconds and is effective for over two hours 1 . Backed by the trust of a legacy brand, it blends proven efficacy with unmatched convenience—all in a compact, pocket-friendly format designed for life on the move.'
The development of this new format was deeply rooted in consumer insights that revealed a growing demand for fast, discreet, and portable solutions to manage acidity. These insights guided Abbott to reimagine the delivery of relief, resulting in a water-free, single-use sachet that aligns with the spontaneous and mobile nature of modern lifestyles. By listening closely to consumer pain points and preferences, Abbott has created a solution that not only meets but anticipates the needs of today's fast-paced world.
To amplify the launch, Digene has rolled out a high-impact, integrated campaign: 'Acidity Kaheen Bhi Ho, Digene Insta On The Go' . This digital-first initiative spans outdoor activations, retail touchpoints, and online platforms—ensuring visibility where it matters most. The campaign includes engaging films such as the Multiplex Film , the Bus Film , and the Adventure Film . Digene Insta On The Go is a new addition to the Digene range, India's No.1 antacid brand 5 , offering consumers another option for managing acidity. Now available at major pharmacies and online platforms across India, Digene Insta On The Go complements Abbott's trusted range of antacid solutions, including Digene Gel and Tablets.
### Refers to the time taken to bring the pH to 3.5, after the amino acid comes in contact with gastric acid. Improved formula refers to higher strength formula with Higher ANC. An invitro study comparing the Preliminary Antacid Test, Acid Neutralizing Capacity and Acid Neutralizing Potential of two antacid products. URAR. Available at: https://www.ijrar.org/IJRAR24D1385.pdf . Dhawal PP, Barve SS. Preliminary in-vitro evaluation of marketed formulations for antacid activity. Int J Basic Clin Pharmacol. 2019:2319-003. Wisely, R. (2018) Why sleep disorders cause heartburn (and vice versa), Why Sleep Disorders Cause Heartburn (and Vice Versa). Available at: https://www.michiganmedicine.org/health-lab/why-sleep-disorders-cause-heartburn-and-vice-versa Heartburn: Causes, symptoms, and treatment (no date) WebMD. Available at: https://www.webmd.com/heartburn-gerd/understanding-heartburn-basics IQVIA Data April 2025
Disclaimer: The above press release comes to you under an arrangement with Business Wire India. Business Upturn take no editorial responsibility for the same.
Ahmedabad Plane Crash
Business Wire India, established in 2002, India's premier media distribution company ensures guaranteed media coverage through its network of 30+ cities and top news agencies.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
an hour ago
- Business Upturn
Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TAK-861) in Narcolepsy Type 1
Business Wire India – Both Phase 3 Studies Met all Primary and Secondary Endpoints Demonstrating Statistically Significant Improvements Across Symptoms at All Doses, Building Upon Phase 2b Results – Oveporexton was Generally Well-Tolerated in Phase 3 Safety Profile – Takeda is Rapidly Advancing Regulatory Submissions and Launch Preparedness with the Aim to Bring Oveporexton to People Living with Narcolepsy Type 1 as Quickly as Possible – These Results Mark a Major Advancement Toward Transforming the Standard of Care by Addressing the Underlying Cause of Narcolepsy Type 1 Takeda (TSE:4502/NYSE:TAK) today announced that all primary and secondary endpoints were met in two Phase 3 randomized, double-blind, placebo-controlled studies of oveporexton (TAK-861), a potential first-in-class investigational oral orexin receptor 2 (OX2R)-selective agonist, in narcolepsy type 1 (NT1). NT1 is caused by the loss of orexin-producing neurons in the brain. Orexin agonists are designed to address this underlying orexin deficiency. For the first time, this mechanism of action has been validated in Phase 3 studies demonstrating significant improvement across a broad range of symptoms. These results reinforce the potential of oveporexton to transform the standard of care. 'We are thrilled to reach this pivotal milestone for the oveporexton program. Oveporexton is a testament to Takeda's strength in discovering and developing a potential new class of medicines for difficult to treat diseases such as narcolepsy type 1,' said Christophe Weber, president and chief executive officer at Takeda. "Our leadership in orexin biology and building a multi-asset orexin franchise with transformative potential will position Takeda for long-term future growth.' The FirstLight (TAK-861-3001) and RadiantLight (TAK-861-3002) studies were two large, global Phase 3 studies conducted in 19 countries. Both studies achieved statistically significant improvement compared to placebo with p-values of <0.001 for all primary and secondary endpoints across all doses at week 12. The primary and secondary endpoints measuring objective and patient reported improvements in wakefulness, excessive daytime sleepiness, cataplexy, ability to maintain attention, overall quality of life and daily life functions demonstrate statistically significant and clinically meaningful improvements achieving near normal ranges across the broad range of symptoms investigated. Oveporexton was generally well-tolerated with a safety profile from the Phase 3 studies overall consistent with oveporexton studies to date including the Phase 2b study. No serious treatment-related adverse events were reported. The most common adverse events were insomnia, urinary urgency and frequency. More than 95 percent of the participants who completed the studies enrolled in the ongoing long-term extension (LTE) study. 'We are grateful to the patients who took part in these clinical studies and to their families, the investigators and clinical staff. The studies were accelerated at an unprecedented pace with the aim to bring this potential treatment to people living with narcolepsy type 1 as quickly as possible,' said Andy Plump, M.D., Ph.D., president of R&D at Takeda. 'The comprehensive assessments from our Phase 3 studies build on the transformative results we saw with our Phase 2b study with most participants reaching normative ranges and reporting clinically meaningful improvement across a broad range of symptoms at the end of the 12-week treatment period. The positive results also reinforce the continued momentum for our late-stage pipeline, which we believe will deliver value to the patients we serve around the world.' Takeda intends to present the results at upcoming medical congresses and plans to submit a New Drug Application with the United States Food and Drug Administration and additional global regulatory authorities in fiscal year 2025. Results from the Phase 3 studies have no significant impact on the full year consolidated forecast for the fiscal year ending March 31, 2026. About Narcolepsy Type 1 (NT1) and Orexin Science NT1 is a chronic, rare neurological disease that results in a range of debilitating symptoms including excessive daytime sleepiness (EDS), cataplexy, disrupted nighttime sleep, sleep paralysis and hallucinations upon falling asleep or waking. Additionally, individuals living with NT1 often report cognitive symptoms, including difficulty thinking clearly, remembering, concentrating and paying attention. NT1 is caused by loss of the orexin-producing neurons in the brain, which regulate wakefulness and sleep, and is also believed to be essential to other functions such as attention through activation of orexin receptors. Currently, the standard of care is limited to symptomatic therapies that may only partially address some of the symptoms people face. About Oveporexton (TAK-861) Oveporexton (TAK-861) is an investigational orexin receptor 2 (OX2R)-selective agonist, which selectively stimulates the OX2R to restore signaling and address the underlying orexin deficiency that causes narcolepsy type 1 (NT1). By activating OX2Rs, oveporexton is designed to promote wakefulness and reduce abnormal rapid eye movement (REM)-sleep like phenomena, including cataplexy, to address the broad spectrum of daytime and nighttime symptoms. About the FirstLight and RadiantLight Phase 3 Studies FirstLight (TAK-861-3001; NCT06470828) and RadiantLight (TAK-861-3002; NCT06505031) are global, multicenter, placebo-controlled studies to evaluate the efficacy, safety and tolerability of oveporexton compared to placebo in patients with narcolepsy type 1 (NT1) over 12 weeks. The studies were conducted in 19 countries with enrollment completed within six months. The FirstLight study enrolled 168 participants randomized to one of three dosing arms (high dose, low dose and placebo). The RadiantLight study enrolled 105 participants randomized to two dosing arms (high dose and placebo). The primary endpoint in both studies was improvement in excessive daytime sleepiness (EDS) as measured by the Maintenance of Wakefulness Test (MWT), a standard measure of wakefulness. Key secondary endpoints included improvement in EDS as measured by the Epworth Sleepiness Scale (ESS) and in the Weekly Cataplexy Rate (WCR), a measure evaluating cataplexy. The studies also evaluated the effect of oveporexton on participants' ability to maintain attention, participants' overall quality of life, the spectrum of narcolepsy symptoms and daily life functions, as well as the safety and tolerability of oveporexton. About Takeda's Orexin Agonists for Sleep-Wake Disorders Takeda is leading the field of orexin science with a multi-asset franchise. Orexin is a key regulator of sleep and wake patterns and contributes to other essential functions including attention, mood, metabolism and respiration. Oveporexton (TAK-861) is the lead investigational orexin receptor 2 (OX2R) agonist asset in Takeda's orexin franchise and received Breakthrough Therapy designation for the treatment of excessive daytime sleepiness in narcolepsy type 1 (NT1) from the U.S. Food and Drug Administration and the Center for Drug Evaluation of China's National Medical Products Administration. The company is also investigating other orexin agonists in populations with orexin levels in the normal range, including TAK-360, an oral OX2R agonist initially being investigated for the treatment of narcolepsy type 2 (NT2), idiopathic hypersomnia (IH), and other potential indications where orexin signaling is implicated. About Takeda Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit Important Notice For the purposes of this notice, 'press release' means this document, any oral presentation, any question-and-answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited ('Takeda') regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws. The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, 'Takeda' is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words 'we', 'us' and 'our' are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies. Forward-Looking Statements This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda's future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as 'targets', 'plans', 'believes', 'hopes', 'continues', 'expects', 'aims', 'intends', 'ensures', 'will', 'may', 'should', 'would', 'could', 'anticipates', 'estimates', 'projects', 'forecasts', 'outlook' or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda's global business, including general economic conditions in Japan and the United States and with respect to international trade relations; competitive pressures and developments; changes to applicable laws and regulations, including tax, tariff and other trade-related rules; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic; the success of our environmental sustainability efforts, in enabling us to reduce our greenhouse gas emissions or meet our other environmental goals; the extent to which our efforts to increase efficiency, productivity or cost-savings, such as the integration of digital technologies, including artificial intelligence, in our business or other initiatives to restructure our operations will lead to the expected benefits; and other factors identified in Takeda's most recent Annual Report on Form 20-F and Takeda's other reports filed with the U.S. Securities and Exchange Commission, available on Takeda's website at: or at Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda's future results. Medical Information This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development. View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire India. Business Upturn take no editorial responsibility for the same. Ahmedabad Plane Crash
Yahoo
2 days ago
- Yahoo
Crisis support line offered for Texans impacted by floods
AUSTIN (KXAN) — Gov. Greg Abbott announced on Friday that the Texas Health and Human Services Commission (HHSC) launched the Texas Flooding Emotional Support Line. The support line was created for Texans who were impacted by recent catastrophic floods, according to Abbott's press office. 'The State of Texas continues working to ensure that Texans hardest hit by these devastating floods have the resources and support they need, and that includes mental health support,' said Governor Abbott. 'This new statewide crisis support line will ensure survivors, families, and first responders have access to emotional support and crisis counseling as they work to heal and recover. The crisis support line is available 24/7 and provides professional crisis counseling at no cost by calling 833-812-2480. All calls are confidential and answered by specially trained professionals to work with disaster survivors, according to the press release. 'The physical and emotional effects from a natural disaster are profound, and can have lasting effects on hearts, minds and communities,' said Michelle Alletto, HHSC chief program and services officer. 'Dedicated mental health support is available to help our fellow Texans cope with loss, rebuild and heal.' Abbott's press office said that through the crisis counseling, Texans can receive disaster recovery options and referrals to other programs. To learn more about the mental health resources available to Texans, visit the Disaster Behavioral Health Services website. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Time Business News
3 days ago
- Time Business News
Unlocking the Future of Diabetes Care: Innovations and Opportunities in Smart Diabetes Management
Revolutionizing Diabetes Management with Cutting-Edge Technology The landscape of diabetes management is experiencing a significant evolution, largely fueled by the incorporation of advanced technologies such as continuous glucose monitoring (CGM) systems, wearable health devices, connected glucometers, and sophisticated mobile applications. These technological advancements provide both patients and healthcare professionals with the ability to monitor glucose levels in real-time, facilitate automated insulin delivery, and create tailored treatment strategies. By enhancing the precision of glucose tracking and treatment adherence, these innovations not only contribute to better health outcomes but also significantly improve the overall quality of life for millions of individuals living with Type 1 and Type 2 diabetes across the globe. Market Growth Fueled by Rising Diabetes Prevalence and Digital Health Advances In 2023, diabetes affects more than 540 million individuals worldwide, a figure projected to rise to 700 million by 2045, underscoring an unprecedented demand for innovative and accessible diabetes management solutions. The increasing utilization of continuous glucose monitors (CGMs), coupled with advancements in artificial intelligence and telehealth, and is transforming the landscape of diabetes care. A significant development in this arena is the recent approval of over-the-counter CGM devices, including Dexcom's Stelo and Abbott's Libre Lingo, which has effectively reduced access barriers and broadened market opportunities, especially in regions that have historically been underserved. This shift not only enhances patient autonomy in managing their condition but also signifies a pivotal moment in the evolution of diabetes care, where technology plays a crucial role in improving health outcomes and quality of life for millions. Emerging Markets: A Hotbed of Growth and Innovation Emerging economies like India, China, and Brazil represent fertile ground for growth, thanks to their large diabetic populations and increasing smartphone penetration. These markets present unique opportunities to develop cost-effective, scalable diabetes management solutions tailored to local needs. Additionally, integrating diabetes platforms with electronic health records (EHRs) and expanding telemedicine services promise to enhance patient care in remote and rural areas, bridging gaps in healthcare accessibility. Pioneering Trends Shaping the Future of Diabetes Care The smart diabetes management space is witnessing an exciting convergence of wearable technology and AI-powered analytics. Real-time glucose monitoring combined with automated insulin delivery systems is making diabetes care more intuitive and responsive than ever. Predictive analytics are enabling patients and clinicians to anticipate blood sugar fluctuations and tailor interventions proactively. Moreover, the rise of long-term implantable sensors, like Senseonics' FDA-cleared Eversense 365, is setting new standards for convenience and adherence by minimizing the need for frequent device replacements. Spotlight on Breakthrough Innovations In May 2024, Smart Meter unveiled the latest iteration of its innovative iGlucose device, a cellular-connected glucose meter that has been a vital tool for over 200,000 individuals managing diabetes since its initial launch in 2019. The newly released model, known as iGlucose Plus, boasts a range of cutting-edge features designed to revolutionize the remote blood glucose monitoring landscape. This advanced version not only enhances the accuracy of diabetes management but also significantly broadens access to essential monitoring technology for millions of patients. In September 2024, Senseonics Holdings, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted clearance for the next-generation Eversense 365 CGM system. This advanced system is designed for adults aged 18 and older with Type 1 and Type 2 diabetes. Notably, the Eversense 365 is recognized as the world's first CGM system capable of providing continuous monitoring for an entire year, marking a significant advancement in diabetes technology and offering new possibilities for improved management of the condition. In March 2024, the U.S. Food and Drug Administration has approved the first over-the-counter continuous glucose monitor (CGM), the Dexcom Stelo Glucose Biosensor System. This integrated CGM (iCGM) is designed for individuals aged 18 and older who do not use insulin, including those managing diabetes with oral medications and non-diabetics interested in monitoring how their diet and exercise affect blood sugar levels. However, it is crucial to note that this system is not suitable for individuals experiencing problematic hypoglycemia, as it does not provide alerts for this potentially hazardous condition. Overcoming Challenges to Accelerate Adoption The path to widespread adoption of advanced technologies is fraught with obstacles, despite the optimistic outlook for the future. Key challenges include persistent concerns regarding data privacy, the need for seamless interoperability among various devices and platforms, and the prohibitive costs associated with implementing sophisticated systems. To facilitate broader acceptance, particularly among vulnerable demographics such as the elderly and low-income individuals, it is essential to focus on enhancing the user experience, ensuring compliance with regulatory standards, and expanding reimbursement options. These strategic efforts will play a crucial role in mitigating barriers and fostering an environment conducive to the integration of innovative solutions into everyday life. The Road Ahead: A Dynamic and Competitive Market Landscape Leading companies like Medtronic, Dexcom, Abbott, Roche, and Tandem Diabetes Care continue to push the envelope with AI-driven digital platforms, seamless device integration, and strategic partnerships. Their focus on personalized, data-centric care and expanding reach into emerging markets is shaping a competitive environment ripe for innovation. With regulatory frameworks evolving to address AI and software as medical devices, the smart diabetes management market is poised for accelerated growth, offering unprecedented opportunities to improve global health outcomes. About Author: HTF Market Intelligence Consulting is uniquely positioned to empower and inspire with research and consulting services to empower businesses with growth strategies, by offering services with extraordinary depth and breadth of thought leadership, research, tools, events, and experience that assist in decision-making. TIME BUSINESS NEWS
